A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily Oral ASC30 in Adult Participants with Obesity or Overweight with Type 2 Diabetes Mellitus (AURORA-2)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-526336-39-00

Enrollment

320

Registered

2026-09-17

Start date

Unknown

Completion date

Unknown

Last updated

2026-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity or Overweight with Type 2 Diabetes Mellitus

Brief summary

From baseline to Week 72 • Percent change in body weight

Detailed description

From baseline to Week 72 •Change in waist circumference (cm), From baseline to Week 72 • Change in SBP (mmHg) • Percent change in fasting - non-HDL cholesterol - triglycerides

Interventions

DRUGASC30

DRUGASC30 Placebo Tablets A1 (Round biconvex tablets)

DRUGASC30 Placebo Tablets A1 (oval-shaped tablets)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
From baseline to Week 72 • Percent change in body weight	—

Secondary

Measure	Time frame
From baseline to Week 72 •Change in waist circumference (cm), From baseline to Week 72 • Change in SBP (mmHg) • Percent change in fasting - non-HDL cholesterol - triglycerides	—

Outcome results

None listed

Source: EU CTIS · Data processed: Sep 18, 2026